SavedAdd your journal

Journals / Journal of Health Sciences and Medicine / 2022 / Cilt: 5 - Sayı: 2

Efficacy of tocilizumab in severe COVID-19: a retrospective study

Seda ÇOLAK
Emre TEKGÖZ
Muhammet ÇINAR
Gülden YILMAZ
Duygu TECER
Fahrettin BIÇAKÇI
Ferhat CUCE
Gonca FİDAN
Deniz DOĞAN
Ümit SAVAŞÇI
Yakup ARSLAN
Cantürk TAŞÇI
Emel UYAR
Zehra KARACAER
Serkan ŞENKAL
Sedat YILMAZ
Pages
592–599
Publication Date
2022-03-15
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The non-survived group had higher rates of mechanical ventilation (MV) support (85.2%) and admission to the intensive care unit (58.8%) (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Coronavirus disease 2019 (COVID-19) is a pandemic with potential life-threatening outcomes.
📊
Key Findings & Data:The current study aims to demonstrate the effect of tocilizumab in COVID-19 related cytokine storm.
💡
Conclusion & Impact:The non-survived group had higher rates of mechanical ventilation (MV) support (85.2%) and admission to the intensive care unit (58.8%) (p
🔬Design:Research Article
📍Scope:2019 Verileri
⚙️Variables:COVID-19 · interleukin 6 · tocilizumab

Abstract

Aim: Coronavirus disease 2019 (COVID-19) is a pandemic with potential life-threatening outcomes. The current study aims to demonstrate the effect of tocilizumab in COVID-19 related cytokine storm. Material and Method: This retrospective cross-sectional study evaluated the patients who received tocilizumab for COVID-19 related cytokine storm between March and August 2020. Demographic, clinical, and laboratory findings were recorded. Computerized tomography (CT) scans, which were performed before tocilizumab infusion were scored. The characteristics of the patients who survived versus those who did not survive were assessed. Results: There was a total of 137 patients, 99 (72.3%) male and 38 (27.7%) female, with a median age of 62 years. Eighty-six (62.7%) patients had severe; 51 (37.2%) patients had critical disease course. The mortality rate was 24.1%. Higher mortality rates were present among patients older than 65 years, females, and with comorbid diseases (p=0.02, p=0.031, and p=0.01, respectively). The non-survived group had higher rates of mechanical ventilation (MV) support (85.2%) and admission to the intensive care unit (58.8%) (p

🔖

Cite This Article

ÇOLAK, S., TEKGÖZ, E., ÇINAR, M., YILMAZ, G., TECER, D., BIÇAKÇI, F., CUCE, F., FİDAN, G., DOĞAN, D., SAVAŞÇI, Ü., ARSLAN, Y., TAŞÇI, C., UYAR, E., KARACAER, Z., ŞENKAL, S., YILMAZ, S. (2022). Efficacy of tocilizumab in severe COVID-19: a retrospective study. Journal of Health Sciences and Medicine, Cilt: 5 - Sayı: 2, 592–599. https://ajindex.com/articles/776614

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis 2020; 34: 101623. Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci 2020; 117: 10970-5.
  2. Lu C-C, Chen M-Y, Lee W-S, Lee Y, Chang L. Potential therapeutic agents against COVID-19: What we know so far. J Chinese Med Assoc 2020; 83: 534-6.
  3. Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med 2020; 382: 2327-36.
  4. Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19. N Engl J Med 2020; 382: 1787-99.
  5. Cai Q, Yang M, Liu D, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering 2020; 6: 1192-8.
  6. Million M, Lagier J-C, Gautret P, et al. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: a retrospective analysis of 1061 cases in Marseille, France. Travel Med Infect Dis 2020; 35: 101738. Behrens EM, Koretzky GA. Review: cytokine storm syndrome: looking toward the precision medicine era. Arthritis Rheumatol 2017; 69: 1135-43.
  7. Keske Ş, Tekin S, Sait B, et al. Appropriate use of tocilizumab in COVID-19 infection. Int J Infect Dis 2020; 99: 338-43.
  8. Morena V, Milazzo L, Oreni L, et al. Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy. Eur J Intern Med 2020; 76: 36-42. Republic of Turkey Ministry of Health COVID-19 (SARS CoV-2 Infection) Guideline. http://covid19.saglik.gov.tr/TR-66341/antisitokin-antiinflamatuar-tedaviler-koagulopati-yonetimi. Accessed November 2020.
  9. Hansell DM, Bankier AA, MacMahon H, et al. Fleischner Society: Glossary of Terms for Thoracic Imaging. Radiology 2008; 246: 697-722.
  10. Ooi GC, Khong PL, Müller NL, et al. Severe acute respiratory syndrome: temporal lung changes at thin-section CT in 30 patients. Radiology 2004; 230: 836-44.
  11. Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol 2015; 16: 448-57.
  12. Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: A single center experience. J Med Virol. 2020; 92: 814-8.
  13. Sciascia S, Aprà F, Baffa A, et al. Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19. Clin Exp Rheumatol 2020; 38: 529-38.
  14. Cifaldi L, Prencipe G, Caiello I, et al.